Miltenyi Biotec Acquires lino Biotech
Miltenyi Biotec, a Bergisch Gladbach, Germany-based company, announced on March 22 that it acquired lino Biotech. Miltenyi Biotec purchased 100% of the shares from investors such as Switzerland-based Roche Venture Fund and Germany-based Hightech-Grunderfonds. Brown Gibbons Lang & Company initiated the transaction and acted as the exclusive financial advisor to lino Biotech. lino Biotech is the world’s only company specialized in focal molography – a new method for measuring molecular interactions in living cells or crude biological samples. It is based in Zurich and was founded in 2020. Miltenyi Biotec has been a global provider of products and services for biomedical research... Read More »
Pfizer Acquires Seagen for $43 Billion
Pfizer Inc. has acquired Seagen Inc. for $43 billion, representing the largest purchase price for a biotechnology deal in 2023. The transaction is expected to be completed in late 2023 or early 2024. Pfizer will pay $229 in cash for each share of Seagen and pay primarily through $31 billion in new, long-term debt. Shares of Pfizer rose 2% to $40.26 after markets opened on March 13 while Seagen’s stock soared more than 15% to nearly $200. Seagen Inc. specializes in working with antibody-drug conjugate technology. Its key products use lab-made proteins called monoclonal antibodies that seek out cancer cells to help deliver a cancer-killing drug while sparing surrounding tissue. It also has a... Read More »
Array BioPharma Grabbed By Pfizer for $11.4 Billion
With AbbVie Inc.’s (NYSE: ABBV) surprise $87 billion bid for Allergan plc (NYSE: AGN) dominating headlines this week, you’d be forgiven for forgetting Pfizer (NYSE: PFE) just bought Array BioPharma (NASDAQ: ARRY) for $11.4 billion only days before. It’s the pharmaceutical giant’s biggest deal of the year thus far in announced dollar volume, and only second behind the aforementioned transaction. The terms included $48 per share in cash, with 237,500,000 shares outstanding, representing a 62% premium to ARRY’s closing price on Friday, June 13. Array BioPharma is a commercial-stage biopharmaceutical company focused on the discovery, development, and... Read More »